A Phase 1 interventional study of Ritlecitinib 50 mg and Ritlecitinib 200 mg in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-13.
Sponsored by Pfizer · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a phase 1, open label, two-arm study to assess target occupancy and functional inhibition of JAK3 and TEC kinases by Ritlecitinib in healthy adult participants
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants are eligible to be included in the study only if all the following criteria apply:
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be dosed with 50 mg Ritlecitinib on Day 1 and followed up till Day 3
Drug: Ritlecitinib 50 mg
Subjects will be dosed with 200 mg Ritlecitinib on Day 1 and followed up till Day 3
Drug: Ritlecitinib 200 mg
50 mg single dose
Also known as: PF-06651600
200 mg single dose
Also known as: PF-06651600
Percent Target Occupancy for JAK3
Target occupancy for janus kinase 3 (JAK3) in peripheral blood mononuclear cells (PBMCs) by ritlecitinib was investigated in human blood by chemical probe-based enrichment and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Percent Target Occupancy for BTK
Target occupancy for Bruton's tyrosine kinase (BTK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Percent Target Occupancy for ITK
Target occupancy forIL 2 inducible T-cell kinase (ITK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Percent Target Occupancy for TXK
Target occupancy for tyrosine kinase expressed in T cells (TXK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Percent Target Occupancy for TEC
Target occupancy for tyrosine kinase expressed carcinoma (TEC) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Percent Target Occupancy for BMX
Target occupancy for bone marrow tyrosine kinase gene in chromosome X (BMX) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point) \*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
Time frame: -1 (pre-dose), 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib
Cmax is maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib
Tmax is time for Cmax. Tmax for ritlecitinib was observed directly from data as time of first occurrence.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib
Clast is last quantifiable plasma concentration. Clast for ritlecitinib was observed directly from data.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib
Cav is average plasma concentration from time 0 to 24 hours over the 24 hours period. Cav for ritlecitinib was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC24) divided by 24.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose
Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib
AUClast is area under the plasma concentration-time profile from time 0 to the time of the Clast. AUClast for ritlecitinib was determined using linear/log trapezoidal method.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24, 48 hours post-dose
Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib
AUC24 is area under the plasma concentration-time curve from time 0 to 24 hours. AUC24 for ritlecitinib was determined using linear/log trapezoidal method.
Time frame: 0 (pre-dose), 1, 2, 4, 8, 24 hours post-dose
Number of Participants With All-Causality and Treatment-Related Treatment-Emergent Adverse Events (TEAEs)
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Number of Participants With Treatment-Emergent Adverse Events by Severity
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. Treatment-emergent are events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Number of Participants With Laboratory Abnormalities Without Regard to Baseline Abnormality
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocyte, platelet, neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, etc), and urinalysis (glucose, protein, hemoglobin, ketones, nitrite, leukocytes, urine bacteria, etc). Baseline = the pre-dose measurement on Day -1. Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. Only those categories in which at least 1 participant had data were reported. ULN=upper limit of normal. LPF=low power field.
Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
Number of Participants With Pre-defined Criteria for Vital Signs
Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) supine DBP: less than (\<) 50 mmHg, b) supine DBP: change of \>= 20mmHg increase, c) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) supine SBP: \<90 mmHg, b) supine SBP: change of \>=30mmHg increase, c) supine SBP: change of \>=30mmHg decrease; 3) Supine pulse rate, a) \<40 bpm, b) \>120 bpm. mmHg=millimeters of mercury, bpm=beats per minute.
Time frame: From the first dose of study treatment up to 35 days after the last dose of study treatment (up to 35 days)
| Milestone | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Started | 8 | 8 |
| Completed | 8 | 8 |
| Not completed | 0 | 0 |
Target occupancy for janus kinase 3 (JAK3) in peripheral blood mononuclear cells (PBMCs) by ritlecitinib was investigated in human blood by chemical probe-based enrichment and liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 72.41 (49.2 to 98.0) | 28.74 (-5.8 to 51.1) |
| 2H | 12.28 (-30.1 to 39.5) | 64.14 (54.1 to 75.0) |
| 4H | -1.39 (-19.6 to 5.2) | 62.06 (45.3 to 73.9) |
| 8H | -23.34 (-49.1 to 17.7) | 58.76 (38.9 to 65.2) |
| 24H | -24.72 (-58.2 to -10.2) | 37.08 (30.2 to 53.1) |
| 48H | -25.34 (-51.8 to 3.7) | 33.44 (9.4 to 52.9) |
Target occupancy for Bruton's tyrosine kinase (BTK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 98.45 (95.4 to 99.8) | 99.57 (98.2 to 99.8) |
| 2H | 96.83 (92.1 to 99.2) | 99.37 (98.6 to 99.8) |
| 4H | 96.43 (90.4 to 99.1) | 99.35 (99.2 to 99.8) |
| 8H | 93.52 (85.3 to 97.8) | 99.21 (97.1 to 99.5) |
| 24H | 83.21 (76.5 to 86.3) | 92.13 (87.0 to 95.5) |
| 48H | 69.86 (63.3 to 76.4) | 82.66 (75.8 to 88.1) |
Target occupancy forIL 2 inducible T-cell kinase (ITK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 94.40 (86.2 to 100.0) | 97.03 (73.8 to 98.0) |
| 2H | 67.77 (42.2 to 88.4) | 97.06 (94.5 to 98.1) |
| 4H | 57.54 (23.0 to 73.9) | 92.27 (86.0 to 97.4) |
| 8H | 28.76 (-5.5 to 58.0) | 76.59 (60.0 to 88.9) |
| 24H | -16.77 (-42.1 to 30.5) | 32.33 (12.4 to 43.8) |
| 48H | -9.87 (-61.0 to 21.6) | 20.62 (-16.0 to 44.7) |
Target occupancy for tyrosine kinase expressed in T cells (TXK) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 100.00 (88.6 to 100.0) | 100.00 (37.7 to 100.0) |
| 2H | 44.97 (27.1 to 66.7) | 100.00 (100.0 to 100.0) |
| 4H | 34.01 (-15.8 to 52.1) | 100.00 (87.9 to 100.0) |
| 8H | 23.17 (-41.0 to 60.7) | 82.46 (63.1 to 100.0) |
| 24H | -4.09 (-43.4 to 31.4) | 49.70 (33.2 to 59.7) |
| 48H | -38.98 (-83.7 to 17.7) | 20.34 (1.9 to 58.8) |
Target occupancy for tyrosine kinase expressed carcinoma (TEC) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point)\*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 96.50 (87.4 to 100.0) | 100.0 (96.0 to 100.0) |
| 2H | 94.60 (88.3 to 98.0) | 99.42 (98.3 to 100.0) |
| 4H | 94.23 (90.9 to 98.3) | 98.78 (98.1 to 100.0) |
| 8H | 93.12 (85.5 to 98.6) | 99.57 (97.4 to 100.0) |
| 24H | 90.64 (83.7 to 95.8) | 96.85 (94.1 to 97.8) |
| 48H | 82.48 (75.7 to 87.3) | 92.32 (87.9 to 94.8) |
Target occupancy for bone marrow tyrosine kinase gene in chromosome X (BMX) in PBMCs by ritlecitinib was investigated in human blood by chemical probe-based enrichment and LC-MS/MS analysis. % TO is calculated as \[(baseline value - value at specified time point) \*100/baseline value\], where baseline value in this formula is defined as the mean of the two pre-dose measurements at Hour -1 and Hour 0 on Day 1. Since (baseline value - value at specified time point)=0 at baseline, % TO at baseline is 0.
| percentage of occupancy | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Baseline | 0.00 (0.0 to 0.0) | 0.00 (0.0 to 0.0) |
| 1H | 67.51 (-16.4 to 96.0) | 99.13 (91.9 to 100.0) |
| 2H | 85.26 (68.5 to 100.0) | 92.53 (88.7 to 100.0) |
| 4H | 84.93 (76.0 to 100.0) | 92.26 (87.7 to 100.0) |
| 8H | 87.08 (69.9 to 95.3) | 92.48 (85.0 to 98.7) |
| 24H | 68.13 (51.5 to 87.9) | 91.32 (82.1 to 97.9) |
| 48H | 26.50 (-15.6 to 54.1) | 62.34 (52.5 to 79.4) |
Cmax is maximum observed plasma concentration. Cmax for ritlecitinib was observed directly from data.
| nanogram/milliliter (ng/mL) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Ritlecitinib | 297.1 ± 51 | 1275 ± 20 |
Tmax is time for Cmax. Tmax for ritlecitinib was observed directly from data as time of first occurrence.
| hour (hr) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Time to Reach Maximum Observed Plasma Concentration (Tmax) of Ritlecitinib | 1.00 (1.00 to 2.00) | 1.00 (1.00 to 2.00) |
Clast is last quantifiable plasma concentration. Clast for ritlecitinib was observed directly from data.
| ng/mL | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Last Quantifiable Plasma Concentration (Clast) of Ritlecitinib | 4.812 ± 87 | 4.036 ± 666 |
Cav is average plasma concentration from time 0 to 24 hours over the 24 hours period. Cav for ritlecitinib was calculated as area under the plasma concentration-time curve from 0 to 24 hours (AUC24) divided by 24.
| ng/mL | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Average Plasma Concentration From Time 0 to 24 Hours (Cav) of Ritlecitinib | 28.42 ± 51 | 144.9 ± 42 |
AUClast is area under the plasma concentration-time profile from time 0 to the time of the Clast. AUClast for ritlecitinib was determined using linear/log trapezoidal method.
| nanogram*hour/milliliter (ng*hr/mL) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast) of Ritlecitinib | 651.4 ± 50 | 3382 ± 43 |
AUC24 is area under the plasma concentration-time curve from time 0 to 24 hours. AUC24 for ritlecitinib was determined using linear/log trapezoidal method.
| ng*hr/mL | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Area Under the Curve From Time 0 to 24 Hours (AUC24) of Ritlecitinib | 681.8 ± 51 | 3475 ± 42 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent were events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state.
| Participants | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Number of Participants with all-causality TEAEs | 3 | 2 |
| Number of Participants with all-causality SAEs | 0 | 0 |
| Number of Participants with treatment-related TEAEs | 0 | 0 |
| Number of Participants with treatment-related SAEs | 0 | 0 |
An AE was any untoward medical occurrence in a participant who received study treatment without regard to possibility of causal relationship. Treatment-related AE was any untoward medical occurrence attributed to study treatment in a participant who received study treatment. Relatedness to study treatment was assessed by the investigator. Treatment-emergent are events between first dose of study treatment and up to 35 days after last dose that were absent before treatment or that worsened relative to pretreatment state. AEs are classified according to the severity in 3 categories a) mild - AEs does not interfere with participant's usual function b) moderate - AEs interferes to some extent with participant's usual function c) severe - AEs interferes significantly with participant's usual function.
| Participants | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Mild (all causalities) | 3 | 2 |
| Moderate (all causalities) | 0 | 0 |
| Severe (all causalities) | 0 | 0 |
| Mild (treatment-related) | 0 | 0 |
| Moderate (treatment-related) | 0 | 0 |
| Severe (treatment-related) | 0 | 0 |
Laboratory parameters included: hematology (hemoglobin, hematocrit, erythrocyte, platelet, neutrophils, eosinophils, monocytes, basophils, lymphocytes, etc), chemistry (glucose, calcium, sodium, potassium, chloride, total bilirubin, aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, protein, albumin, etc), and urinalysis (glucose, protein, hemoglobin, ketones, nitrite, leukocytes, urine bacteria, etc). Baseline = the pre-dose measurement on Day -1. Laboratory abnormalities meeting pre-defined criteria are reported for this outcome measure. Only those categories in which at least 1 participant had data were reported. ULN=upper limit of normal. LPF=low power field.
| Participants | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Monocytes/Leukocytes (%) >1.2*ULN | 0 | 2 |
| Urine Nitrite >=1 | 1 | 1 |
| Urine Bacteria (/LPF) >20 | 1 | 0 |
Pre-defined criteria included: 1) Diastolic blood pressure (DBP), a) supine DBP: less than (\<) 50 mmHg, b) supine DBP: change of \>= 20mmHg increase, c) supine DBP: change of \>= 20mmHg decrease; 2) Systolic blood pressure (SBP), a) supine SBP: \<90 mmHg, b) supine SBP: change of \>=30mmHg increase, c) supine SBP: change of \>=30mmHg decrease; 3) Supine pulse rate, a) \<40 bpm, b) \>120 bpm. mmHg=millimeters of mercury, bpm=beats per minute.
| Participants | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Supine DBP <50 mmHg | 0 | 0 |
| Supine DBP change >= 20mmHg increase | 0 | 0 |
| Supine DBP change >= 20mmHg decrease | 0 | 0 |
| Supine SBP <90 mmHg | 0 | 0 |
| Supine SBP change >=30mmHg increase | 0 | 0 |
| Supine SBP change >=30mmHg decrease | 0 | 0 |
| Supine pulse rate <40 bpm | 0 | 0 |
| Supine pulse rate >120 bpm | 0 | 0 |
Collected over Baseline up to 35 days after the last dose of study treatment on Day 1 (up to 35 days). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RITLECITINIB 50 MG CAPSULE | 0/8 (0%) | 0/8 (0%) | 3/8 (37.5%) |
| RITLECITINIB 200 MG CAPSULE | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Event | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE |
|---|---|---|
| Abdominal distensionGastrointestinal disorders | 1/8 | 0/8 |
| DyspepsiaGastrointestinal disorders | 1/8 | 0/8 |
| Escherichia urinary tract infectionInfections and infestations | 1/8 | 0/8 |
| Gastroenteritis viralInfections and infestations | 0/8 | 1/8 |
| Procedural dizzinessInjury, poisoning and procedural complications | 0/8 | 1/8 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 1/8 | 0/8 |
Baseline analysis population included all enrolled participants who received at least one dose of study treatment.
| Age, Continuous(Years) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE | Total |
|---|---|---|---|
| Mean | 43.9 ± 10.95 | 37.9 ± 12.97 | 40.9 ± 12.0 |
| Age, Customized(Participants) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE | Total |
|---|---|---|---|
| <18 | 0 | 0 | 0 |
| 18-44 | 3 | 4 | 7 |
| 45-64 | 5 | 4 | 9 |
| >=65 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE | Total |
|---|---|---|---|
| Female | 4 | 2 | 6 |
| Male | 4 | 6 | 10 |
| Ethnicity (NIH/OMB)(Participants) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 1 |
| Not Hispanic or Latino | 7 | 8 | 15 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | RITLECITINIB 50 MG CAPSULE | RITLECITINIB 200 MG CAPSULE | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 2 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 3 | 2 | 5 |
| White | 4 | 4 | 8 |
| More than one race | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2021 to primary completion in Jan 2022, 2 months.
Results were first posted in Nov 2023, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: PF-06651600